Last updated: Nov 7, 2025 (19:23 UTC)
Pfizer (NYSE: PFE) shares were trading around $24.28, down roughly 2.3% intraday, as investors weighed new twists in the Metsera takeover fight and marked today’s dividend record date. As of the latest print, the stock’s day range was $24.12–$24.61 on heavy volume.
Key takeaways
- Price action: PFE trades near $24.28, about –2.3% on the day (range $24.12–$24.61; intraday volume >67M).
- Metsera showdown: The obesity‑drug bidding war escalates after a Delaware judge declined to block Metsera from ending its Pfizer deal, while reporting indicates Pfizer may sweeten its offer; Novo Nordisk has publicly pushed Pfizer to raise its bid. A shareholder vote is slated for Nov 13. [1]
- Earnings context: Earlier this week, Pfizer beat Q3 expectations and raised EPS guidance to $3.00–$3.15 for 2025, with adjusted EPS at $0.87 on $16.65B in sales. [2]
- Dividend milestone today:Record date is Nov 7 for the $0.43 quarterly payout, payable Dec 1, 2025—Pfizer’s 348th consecutive dividend. [3]
Pfizer stock price today (intraday)
- Price (19:23 UTC):$24.28
- Change:–$0.58 (~–2.31%) vs. prior close
- Day range:$24.12–$24.61
- Intraday volume:67,080,164
These figures reflect real‑time market conditions and can change rapidly.
What changed today — Nov 7, 2025
1) Metsera bidding war heats up
- Court development: On Nov 5, a Delaware judge said she would not block Metsera from terminating its agreement with Pfizer, clearing the way for Metsera to pursue Novo Nordisk’s higher offer. That ruling keeps pressure on Pfizer to respond. [4]
- Pfizer’s next move: Reporting on Nov 6 indicated Pfizer removed some conditions and may sweeten its bid for Metsera as the contest intensifies. [5]
- Public pressure & timeline: Novo has publicly challenged Pfizer to raise its offer, and a Metsera shareholder vote is set for Nov 13—a near‑term catalyst for PFE. [6]
- Deal size context: Novo’s latest proposal values Metsera up to ~$10B, topping Pfizer’s prior agreement and underscoring the strategic stakes in anti‑obesity medicines. [7]
Why it matters: The Metsera outcome could reshape Pfizer’s cardiometabolic/obesity ambitions after earlier setbacks, and investors are repricing PFE daily on any signal of who ultimately wins—and at what cost. [8]
2) Earnings and guidance are a supportive backdrop
On Nov 4, Pfizer posted adjusted EPS of $0.87 on $16.65B in revenue, raised and narrowed its 2025 EPS outlook to $3.00–$3.15, and cited stronger execution across non‑COVID brands. Those beats help frame today’s move within a broader recovery narrative. [9]
3) Dividend record date lands today
Investors of record today (Nov 7) qualify for the $0.43 quarterly dividend, payable Dec 1, 2025. At the current share price, the implied annual yield is ~7.1% based on $1.72 per year. Note: ex‑dividend timing is set by the exchange; Pfizer’s release specifies record and payable dates. [10]
4) Other headlines to note
- Regulatory context: On Oct 31, Pfizer said the FTC granted early termination of the HSR waiting period tied to its Metsera deal—preceding this week’s legal/judicial developments. [11]
- Advertising dispute: Today, the National Advertising Division said it will refer BridgeBio Pharma to government agencies after a challenge submitted by Pfizer—a minor story but part of the day’s tape. [12]
What to watch next
- Metsera vote (Nov 13): The shareholder decision—and any revised bids—could be a binary catalyst for PFE in the coming days. [13]
- Strategic clarity: If Pfizer does raise its offer, investors will parse deal economics (cash vs. CVRs, contingencies) and timeline risk. [14]
- Execution vs. guidance: After the Q3 beat and guidance raise, watch non‑COVID franchises and margin progress against 2025 targets. [15]
Quick FAQ
Why is Pfizer stock moving today?
Most of today’s volatility traces to the Metsera bidding war (court ruling, potential sweetened bid, and public pressure from Novo), set against the backdrop of this week’s earnings beat and raised guidance. [16]
What is Pfizer’s dividend situation right now?
Record date is Nov 7 for the $0.43 quarterly dividend, payable Dec 1, 2025, marking the company’s 348th consecutive payment. [17]
Where is PFE trading intraday?
Around $24.28 at 19:23 UTC, with a –2.3% move on the session and a $24.12–$24.61 range so far.
Bottom line
For Nov 7, 2025, Pfizer’s share price reflects a tug‑of‑war between near‑term deal risk (Metsera) and improving fundamentals (raised guidance, steady dividend). The next major catalyst is Nov 13—keep an eye on any revised bids and the shareholder vote outcome. [18]
This article is for information purposes only and is not investment advice. Always do your own research or consult a licensed financial advisor before making trading decisions.
References
1. www.reuters.com, 2. markets.ft.com, 3. www.pfizer.com, 4. www.reuters.com, 5. www.reuters.com, 6. www.ft.com, 7. apnews.com, 8. www.ft.com, 9. markets.ft.com, 10. www.pfizer.com, 11. www.pfizer.com, 12. www.globenewswire.com, 13. www.ft.com, 14. www.reuters.com, 15. markets.ft.com, 16. www.reuters.com, 17. www.pfizer.com, 18. www.ft.com
